Pulmonary Hypertension News and Research RSS Feed - Pulmonary Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Health Integrated, a leader in precision care management solutions, released the results today of an annual health plan survey jointly commissioned with the Association for Community Affiliated Plans, a national trade association representing nonprofit safety net health plans. [More]
New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

Experts from the Johns Hopkins Center for Sleep hope to help patients get a better night’s sleep by providing health care staff members with a basic educational tool on their smartphones. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Combining CT measurements assists pulmonary hypertension prediction

Combining CT measurements assists pulmonary hypertension prediction

Research suggests that combining pulmonary artery and ventricular measurements improves the chances of identifying pulmonary hypertension in patients undergoing computed tomography pulmonary angiography. [More]
Inhaled Nitric Oxide still being used in preterm neonates despite evidence of short-term benefit

Inhaled Nitric Oxide still being used in preterm neonates despite evidence of short-term benefit

Inhaled Nitric Oxide (iNO) is a drug approved by the Food and Drug Administration that is commonly used in term and near-term neonates who have severe respiratory failure caused by pulmonary hypertension. Over the last decade there have been multiple large studies trying to determine a clinical use for iNO in preterm neonates, but despite evidence of short-term benefit, this drug has not been shown to improve long-term outcomes in preemies. [More]
Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion. [More]
Study explores outcomes of lung transplantations after implementing need-based allocation system

Study explores outcomes of lung transplantations after implementing need-based allocation system

Since implementation of a medical need-based allocation system of donor lungs in 2005, double-lung transplantation has been associated with better graft survival than single-lung transplantation in patients with idiopathic pulmonary fibrosis (IPF); at 5 years, there has been no survival difference between single- and double-lung transplant recipients in patients with chronic obstructive pulmonary disease (COPD), according to a study in the March 3 issue of JAMA. [More]
Research finding could lead to new therapeutic target for treating hypertension in males

Research finding could lead to new therapeutic target for treating hypertension in males

Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say. [More]
PAH survival unaffected by rheumatoid arthritis origin

PAH survival unaffected by rheumatoid arthritis origin

Patients with rheumatoid arthritis-associated pulmonary arterial hypertension have comparable survival to those with idiopathic pulmonary arterial hypertension, researchers report. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
Researchers find way to prevent noise-induced hearing loss

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein. [More]
New model explains how immune cells recognize, destroy bacteria

New model explains how immune cells recognize, destroy bacteria

The innate immune system serves as the body's specialized armed forces division, comprised of a host of defense mechanisms used to battle bacterial infections. Among the system's warriors are white blood cells including the specialized macrophages, which maintain constant surveillance for foreign intruders or pathogens, functioning as the body's first line of defense, poised to attack at barrier sites including the skin, lungs and intestines. [More]
UAlberta researchers discover link between pulmonary hypertension, diabetes and cancer

UAlberta researchers discover link between pulmonary hypertension, diabetes and cancer

A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease. [More]
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]
Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects. [More]
Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study. [More]
Cardiac arrhythmias pose risk in pulmonary hypertension patients

Cardiac arrhythmias pose risk in pulmonary hypertension patients

Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows. [More]
Expert creates new evidence-based guideline for managing sickle cell disease

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA. [More]
Advertisement
Advertisement